Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679649 | 1.00 | PTPRB (0.65) | PTPRBPTPN11 | |
| SCHEMBL29794256 | 1.00 | PTPRB (0.65) | PTPRBPTPN11 | |
| SCHEMBL16079950 | 0.88 | PTPRB (0.65) | PTPRBPTPN11 | |
| SCHEMBL500493 | 0.85 | PTPRB (0.63) | PTPRBPTPN11 | |
| SCHEMBL500494 | 0.85 | PTPRB (0.63) | PTPRBPTPN11 | |
| SCHEMBL27940604 | 0.85 | PTPRB (0.45) | PTPRB | |
| SCHEMBL468172 | 0.85 | PTPRB (0.61) | PTPRBPTPN11 | |
| SCHEMBL29794262 | 0.85 | PTPRB (0.61) | PTPRBPTPN11 | |
| SCHEMBL501040 | 0.85 | PTPRB (0.61) | PTPRBPTPN11 | |
| SCHEMBL3551815 | 0.85 | PTPRB (0.46) | PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451279-B1 | BENZOSULFONAMIDE DERIVATIVES, COMPOSITIONS THEREOF, AND THEIR USE IN PREVENTING METASTASIS OF CANCER CELLS | AERPIO THERAPEUTICS INC (US) | 2019-03-13 | — | — | EP | claimed |
| EP-2385763-B1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | AERPIO THERAPEUTICS INC (US) | 2018-04-18 | — | — | EP | claimed |
| EP-2038265-B1 | Human protein-tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS INC (US) | 2015-03-18 | — | — | EP | claimed |
| US-20140378445-A9 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2014-12-25 | — | — | US | claimed |
| US-8883832-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS INC. (US) | 2014-11-11 | — | — | US | claimed |
| US-20140249100-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | AERPIO THERAPEUTICS INC. (US) | 2014-09-04 | — | — | US | claimed |
| US-20140179693-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | SHALWITZ ROBERT (US) | 2014-06-26 | — | — | US | claimed |
| US-20140066458-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2014-03-06 | — | — | US | claimed |
| US-20130331386-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2013-12-12 | — | — | US | claimed |
| US-8569348-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS INC. (US) | 2013-10-29 | — | — | US | claimed |
| US-20130023542-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-01-24 | — | — | US | claimed |
| US-20120128625-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EyePoint, Inc. | 2012-05-24 | — | — | US | claimed |
| US-20120129847-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2012-05-24 | — | — | US | claimed |
| WO-2012047966-A2 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | AKEBIA THERAPEUTICS INC. (US) | 2012-04-12 | — | — | WO | claimed |
| EP-2385763-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | Akebia Therapeutics Inc. (US) | 2011-11-16 | — | — | EP | claimed |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2011-11-03 | — | — | US | claimed |
| US-20110253725-A1 | MULTI-PORT BEVERAGE AND FOOD CONTAINERS | KILLIAN WILLIAM | 2011-10-20 | — | — | US | claimed |
| EP-2038265-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-03-25 | — | — | EP | claimed |
| WO-2008002570-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | claimed |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129847-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | PTPRB 1894/4885PTPN11 410/4885 |
| US-20140066458-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | PTPRB 551/4885PTPN11 3648/4885 |
| US-20120128625-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EPCAM, CD44, CDH1 | PTPRB 1445/4885PTPN11 3125/4885 |
| US-20140378445-A9 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, EPCAM | PTPRB 422/4885PTPN11 3321/4885 |
| US-20140249100-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EPCAM, CD44, CDH1 | PTPRB 1445/4885PTPN11 3125/4885 |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | PTPRB 551/4885PTPN11 3648/4885 |
| US-20130331386-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | PTPRB 551/4885PTPN11 3648/4885 |
| US-20140179693-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, EPCAM | PTPRB 422/4885PTPN11 3321/4885 |
| US-20130023542-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885PTPN11 88/4885 |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885PTPN11 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.